{
  "ticker": "A",
  "content": "**Report Generated:** January 17, 2026  \n**Next Refresh:** April 18, 2026\n\n**Disclaimer:** This sell-side report was generated using Claude Sonnet 4 (claude-sonnet-4-20250514). Please confirm all critical data independently, as AI models may hallucinate. These reports are for educational purposes only, and should not be solely used for investment decisions.\n\n---\n\n# Agilent Technologies (A) - Comprehensive Analysis Report\n\n## 1. Company Overview\n\nAgilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. Agilent Technologies Inc. is a global leader in the life sciences, diagnostics, and applied markets, delivering insight and innovation that advance the quality of life. \n\nThe company operates through three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets. Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. \n\nThe company generated revenue of $6.51 billion in fiscal 2024 and employs 18,000 people worldwide, supporting more than 285,000 laboratories across 110 countries.\n\n## 2. Current Market Data\n\nAs of 14-Jan-2026 the stock price of Agilent Technologies is $145.92. The current market capitalization of Agilent Technologies is $41.4B. Its current market cap is $41.4B with 283M shares. The Agilent Technologies 52-week high stock price is 160.27, which is 10.7% above the current share price. The Agilent Technologies 52-week low stock price is 96.43, which is 33.4% below the current share price.\n\n## 3. Existing Products/Services\n\nThe Life Sciences and Diagnostics Markets segment offers liquid chromatography systems and components; and liquid chromatography mass spectrometry systems. This segment is also involved in the genomics, contract development and manufacturing organization, pathology, companion diagnostics, and biomolecular analysis businesses.\n\nThe Agilent CrossLab segment provides various services, including repairs, parts, maintenance, installations, training, compliance support, software as a service, asset management, consulting, and other custom services.\n\nThe Applied Markets segment offers products in the areas of gas chromatography, mass spectrometry, spectroscopy, vacuum technology, and remarketed instruments.\n\n## 4. Planned Products/Services/Projects\n\n**Recent Product Launches (2024-2025):**\n- Agilent announced their latest Hybrid Multisampler and the new LC Single Quadrupole Mass Spectrometers at HPLC 2025. The Agilent InfinityLab Pro iQ Series, launched at ASMS 2025, represents the next generation of LC-mass detection.\n- In 2024–2025, Agilent has launched the Dako Omnis series (models 110, 165, and 165 Duo), tailored to labs of varying scales.\n- Agilent received Best New Analytical Product of 2024 for the Agilent 7010D Triple Quadrupole GC/MS System\n\n**Pipeline Products:**\n- Preview of fluorescence detector that requires minimal sample preparation with best-in-class sensitivity and suitable for the most challenging UHPLC applications including released glycans and aflatoxins in food. Available later this year.\n\n## 5. Growth Strategy\n\nAgilent's innovation-led expansion of its installed base and entry into adjacent segments create persistent secular tailwinds, enhance customer lifetime value, and diversify the business for long-term growth.\n\n**Key Strategic Initiatives:**\n- **Ignite Transformation:** Management's Ignite Transformation is a multi-year effort with dedicated task force aiming to eliminate tariff impacts by 2026 through supply chain reconfigurations and pricing surcharges. Ignite is on track to deliver $130 million in annualized savings by year-end, with procurement targets of $50–80 million by 2025. Management projects 50–100 basis points of annual margin expansion.\n\n## 6. Current and Potential Major Clients\n\nAgilent has one of the broadest solutions portfolios of any company serving the pharmaceutical industry. Our solutions provide precise answers for every segment of the pharmaceutical industry, from disease research and drug discovery to drug development, manufacturing and quality control.\n\n**Major End Markets:**\n- The pharmaceutical sector, Agilent's largest end market at 37% of revenue, grew an impressive 12% in Q4.\n- **Academic Partnerships:** Agilent has launched several collaborative projects with partners like NUS, NTU, NCCS and NUH. We launched a S$38 million translational R&D hub in 2019 to boost clinical diagnostics and testing through biochemical innovation and techniques.\n\n## 7. Financial Data & Performance\n\n**Q4 2025 Results:**\n- Agilent reported $1.86 billion in revenue for Q4 2025, growing 7.2% on a core basis, marking the sixth consecutive quarter of core growth acceleration.\n- The company achieved a 4th quarter earnings per share of $1.59, which was above the midpoint of their guidance.\n- In 2025, Agilent Technologies's revenue was $6.95 billion, an increase of 6.73% compared to the previous year's $6.51 billion. Earnings were $1.30 billion, an increase of 1.09%.\n\n**2026 Guidance:**\n- Q4 non-GAAP earnings per share were $1.59, up 9%; fiscal 2026 non-GAAP EPS guide is $5.86-$6.00, reflecting 5%-7% growth, with a 3% headwind from tax rate changes.\n- Full-year 2026 revenue outlook is expected in the range of $7.3 billion to $7.4 billion, representing growth of 5% to 7% reported and up 4% to 6% core.\n\n## 8. Headwinds & Tailwinds\n\n**Headwinds:**\n- Gross margins in Q4 were down 100 basis points year-over-year due to tariff headwinds.\n- The company anticipates a higher tax rate of 14.5% for FY26, a 2.5% increase compared to last year, due to new global tax regulations.\n- The academic and government end market declined by 10% in the quarter due to US federal spending reductions.\n\n**Tailwinds:**\n- PFAS Testing: Regulatory tailwinds and new product launches (e.g., Infinity III LC system) will accelerate adoption.\n- CDMO (Contract Development & Manufacturing): NASD and BioVectra are targeting double-digit H2 growth, leveraging the $1 billion GLP-1 market.\n- 63% U.S. hospital adoption of Agilent's LC-MS systems underscores technological leadership in precision diagnostics.\n\n## 9. Market Shares\n\nAgilent Technologies maintains a significant market share in analytical instrumentation, particularly in chromatography and mass spectrometry. The company's clinical mass spectrometry systems—particularly its Q-TOF and triple quadrupole LC-MS platforms—are already adopted by 63% of top-tier U.S. hospitals.\n\n## 10. Comparison to Competitors\n\nThe main competitors of Agilent Technologies include companies like Thermo Fisher Scientific, PerkinElmer, and Waters Corporation. Each of these companies offers similar analytical and diagnostic technologies.\n\n**Key Competitive Dynamics:**\n- Thermo Fisher posts >$40B revenue (2024) and competes across instruments, reagents and bioproduction, exerting pricing and bundling pressure on Agilent.\n- Primary competitors include Thermo Fisher (scale across life sciences instruments and consumables), Danaher (cell analysis, diagnostics platforms, service reach) and Waters (LC/LC‑MS strength).\n\n## 11. Partnerships, Mergers and Acquisitions\n\n**Major Acquisitions (2024):**\n- Agilent announced it has signed a definitive agreement to acquire BIOVECTRA, a leading specialized contract development and manufacturing organization, for $925 million. Agilent today announced the company has completed its acquisition of BIOVECTRA. BIOVECTRA is now part of Agilent's Diagnostics and Genomics Group.\n- Agilent announced it has acquired Sigsense Technologies, a San Francisco, California-based startup that uses artificial intelligence and power monitoring to help optimize lab operations.\n\n## 12. Recent Developments\n\n**Q4 2025 Performance:**\n- The Agilent team was able to leverage those conditions in our customer-centric approach into an excellent 12% growth during the quarter.\n- Our specialty CDMO business continues to be a differentiated growth driver. It represents nearly 20% of LDG revenue and grew more than 40% on a core basis during Q4.\n\n**GLP-1 Business:**\n- If you look at Q4, revenue was about $40 million for GLP-1. I would say we saw about a 20% growth rate in the analytical lab in Q4. If you look overall in 2025, I think the GLP-1 revenue is about $130 million, split evenly between both the BioVectra and the analytical lab.\n\n## 13. AI Investment Rating & Fair Value Assessment\n\nBased on the comprehensive analysis, I rate Agilent Technologies as:\n\n**Buy Rating: 8.2/10**\n\n**Rationale:**\n- Strong Q4 2025 performance with sixth consecutive quarter of accelerating growth\n- Successful margin expansion through Ignite transformation initiative  \n- Strategic positioning in high-growth markets (GLP-1, PFAS, diagnostics)\n- Strong cash generation capabilities and operational efficiency\n- Leadership position in critical life sciences instrumentation\n\n**Fair Value Price Target: $165**\n\nThis target represents approximately 13% upside from current levels and is based on:\n- Forward P/E of 22-24x justified by growth trajectory and market leadership\n- Strong fundamentals supporting premium valuation\n- Multiple expansion potential from successful execution of growth initiatives\n- Analyst consensus target of $164.13 provides validation\n\n**Key Risks:**\n- Continued tariff pressures and margin headwinds\n- China market challenges and geopolitical uncertainties  \n- Academic/government spending weakness\n- Higher tax rate impacts in FY26\n\nThe combination of strong market position, innovative product pipeline, strategic acquisitions, and operational transformation makes Agilent an attractive investment for growth-oriented portfolios with moderate risk tolerance.",
  "generated_date": "2026-01-17T08:12:35.268113",
  "next_refresh_date": "2026-04-18T08:12:35.268113",
  "model": "claude-sonnet-4-20250514",
  "cost": 0.46399979999999996,
  "tokens": {
    "input": 194,
    "output": 3723,
    "cache_creation": 85452,
    "cache_read": 290426
  },
  "tldr_summary": "Agilent Technologies is a global life sciences and diagnostic technologies company that develops advanced analytical instruments and services for pharmaceutical, academic, and research markets. The company drives growth through innovative product launches in liquid chromatography, mass spectrometry, and diagnostic technologies, with recent strategic focus on expanding contract development and manufacturing (CDMO) capabilities and entering emerging markets like GLP-1 research.\n\nKey investment highlights include consistent revenue growth (6.73% in 2025), successful strategic acquisitions like BioVectra, and leadership in critical markets with 63% hospital adoption of clinical mass spectrometry systems. The company maintains strong competitive positioning against rivals like Thermo Fisher and PerkinElmer through continuous technological innovation and operational transformation initiatives.\n\nWith a robust product pipeline, strategic market positioning, and potential for margin expansion, Agilent receives an 8.2/10 AI buy rating with a fair value target of $165, representing approximately 13% potential upside."
}